Stifel Financial Corp Sells 3,489 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stifel Financial Corp cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 68,524 shares of the pharmaceutical company’s stock after selling 3,489 shares during the period. Stifel Financial Corp’s holdings in Vertex Pharmaceuticals were worth $11,662,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Next Capital Management LLC boosted its holdings in Vertex Pharmaceuticals by 84.4% in the 2nd quarter. Next Capital Management LLC now owns 166 shares of the pharmaceutical company’s stock worth $30,000 after buying an additional 76 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its holdings in Vertex Pharmaceuticals by 118.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 177 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 96 shares during the period. HM Payson & Co. bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $35,000. Captrust Financial Advisors boosted its holdings in Vertex Pharmaceuticals by 204.1% in the 2nd quarter. Captrust Financial Advisors now owns 222 shares of the pharmaceutical company’s stock worth $41,000 after buying an additional 149 shares during the period. Finally, Motco bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $44,000. 94.87% of the stock is owned by institutional investors.

Vertex Pharmaceuticals stock opened at $220.79 on Tuesday. The firm’s fifty day moving average price is $200.93 and its 200-day moving average price is $181.81. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.32 and a current ratio of 3.44. The stock has a market cap of $57.02 billion, a P/E ratio of 78.02, a price-to-earnings-growth ratio of 2.03 and a beta of 1.49. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $151.80 and a fifty-two week high of $223.73.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, October 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.36. The firm had revenue of $949.83 million for the quarter, compared to analysts’ expectations of $942.90 million. Vertex Pharmaceuticals had a net margin of 59.24% and a return on equity of 20.33%. The business’s quarterly revenue was up 21.1% on a year-over-year basis. During the same quarter last year, the company posted $1.09 EPS. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 3.72 earnings per share for the current year.

Several research analysts recently commented on the stock. BMO Capital Markets raised their price objective on shares of Vertex Pharmaceuticals to $248.00 and gave the stock a “positive” rating in a report on Wednesday, November 20th. Citigroup raised their price objective on shares of Vertex Pharmaceuticals from $205.00 to $225.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Jefferies Financial Group set a $220.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 21st. Morgan Stanley raised their price objective on shares of Vertex Pharmaceuticals from $215.00 to $240.00 and gave the stock an “overweight” rating in a report on Friday, September 6th. Finally, BidaskClub raised shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and an average price target of $219.07.

In other news, CEO Jeffrey M. Leiden sold 107,831 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $190.00, for a total transaction of $20,487,890.00. Following the sale, the chief executive officer now owns 178,707 shares in the company, valued at approximately $33,954,330. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Ourania Tatsis sold 188 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $169.11, for a total transaction of $31,792.68. Following the sale, the senior vice president now owns 7,696 shares in the company, valued at approximately $1,301,470.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 290,475 shares of company stock worth $56,792,441. Corporate insiders own 0.70% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Featured Story: FinTech

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.